

WD

RECEIVED  
OCT 28 1999  
1635  
7/3/10  
ehh

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Inte patent application of:
Caput et al.
Serial No.: 09/077,817
Filed: September 14, 1998
Group Art Unit: 1635
Examiner: Sean McGarry
For: IL-13 RECEPTOR

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being deposited on the date indicated below with the United States Postal Service as first class mail addressed to: Box Sequence, Assistant Commissioner for Patents, Washington, DC 20231

Name	Kathy Smith Dias
Date	10/21/99

Box Sequence  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**SUBMISSION OF "SEQUENCE LISTING"**  
**UNDER 37 CFR 1.821**

Dear Sir:


This is in response to the Office communication (paper no. 12) mailed October 1, 1999. Response is due by November 1, 1999; this response is, therefore, timely filed.

Enclosed are (1) a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures; (2) a computer readable copy of the Sequence Listing for the above-identified application; and (3) a substitute paper copy of the "Sequence Listing"; (4) an amendment directing its entry into the specification and (5) a statement that the computer readable copy and substitute paper copy of the sequence listing are the same.

Date: 10/21/99

Respectfully submitted,  
Kathy Smith Dias  
Kathy Smith Dias  
Reg. No. 41,707

Address:  
Patent Department  
Sanofi Pharmaceuticals, Inc.  
9 Great Valley Parkway  
P.O. Box 3026  
Malvern, PA 19355  
Tele: (610) 889-8802  
Fax: (610) 889-8799



Application No.: 09/077,817

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: PLEASE SEE ATTACHED PTOL90 COMMUNICATION.

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:	<b>CERTIFICATE UNDER 37 C.F.R. 1.8(a)</b>
Caput et al.	I hereby certify that this correspondence is being
Serial No.: 09/077,817	deposited on the date indicated below with the
	United States Postal Service as first class mail
Filed: September 14, 1998	addressed to: Box Sequence, Assistant
	Commissioner for Patents,
	Washington, DC 20231
Group Art Unit: 1635	
	Name <i>Kathy Smith Dias</i>
Examiner: Sean McGarry	
	Date <i>10/21/99</i>
For: IL-13 RECEPTOR	

Box Sequence  
Assistant Commissioner for Patents  
Washington, D.C. 20231

**STATEMENT UNDER 37 CFR 1.821(f) and(g)**

Dear Sir:

Applicants' undersigned representative states that the content of the substitute paper copy of the sequence listing of the above-captioned patent application and the computer readable copy filed herewith on computer disk are the same and that they include no new matter.

Respectfully submitted,

Date: 10/21/99

Address:  
Patent Department  
Sanofi Pharmaceuticals, Inc.  
9 Great Valley Parkway  
P.O. Box 3026  
Malvern, PA 19355  
Tele: (610) 889-8802  
Fax: (610) 889-8799

*Kathy Smith Dias*  
Kathy Smith Dias  
Reg. No. 41,707